News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


MSNZ welcomes consultation period for Tysabri and Gilenya

Media release (8 August 2014)


MSNZ welcomes beginning of consultation period for Tysabri and Gilenya as proposed new first-line treatments for relapsing remitting forms of Multiple Sclerosis.

The Multiple Sclerosis Society of New Zealand (MSNZ) welcomes PHARMAC’s release of a consultation document today that proposes Natalizumab (Tysabri)and Fingolimod (Gilenya) as potential new first-line treatments for relapsing, remitting forms of MS.

PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including these two new treatments. It is also seeking feedback on potential changes to the currently funded treatments Avonex, Betaferon and Copaxone.

In February, PTAC (the Pharmaceutical Technical Advisory Committee) recommended to PHARMAC that these new treatments be funded as new first-line treatments.

“It has been a long process to get to this point but PHARMAC’s announcement is a positive step,” says MSNZ spokesman Neil Woodhams. “Relapsing Remitting MS is one of four types of MS, affecting the highest percentage of patients. These new treatments, if accepted by PHARMAC, will be given as soon after diagnosis as possible, to patients fitting within the criteria. This is a great start for all those who will benefit from these treatments.”

Subject to a positive outcome from its consultation process, PHARMAC has suggested that Natalizumab and Fingolimod could be listed on the Hospital Medications List by 1 November 2014 and that changes to the restrictions around access to treatments that are currently funded could also be made by that date.

“This is not the end of the process,” says Mr Woodhams. “The next stage of consultation begins today. We recommend that interested parties read the consultation documents carefully as there are restrictions on the access to these treatments and changes that will be made to the currently-funded treatments.”

Submissions on PHARMAC’s consultation document close on 29 August, 2014.

“MSNZ would like to thank everyone involved in the Patients’ Steering Group, the MS Community, neurologists and supporters who have helped to highlight the importance of funding these new first-line treatments. MSNZ has been overwhelmed with the support and commitment shown to date and we urge supporters to maintain their level of engagement during the next stage of the process and beyond.”


More information about the consultation documents:
For more information visit the PHARMAC website:
www.pharmac.health.nz/news/consultation-2014-08-07-mstreatments/

Details of the proposal, including proposed funding access criteria, and some background information can be found at:
www.pharmac.health.nz/assets/consultation-2014-08-07-mstreatments.pdf

Please note: The fingolimod component of this proposal is dependent on a multi-product provisional agreement with Novartis, for a number of other products including fingolimod, being approved. PHARMAC are consulting on the Novartis multiproduct proposal separately, see PHARMAC’s website at: www.pharmac.health.nz/news/consultation-2014-08-07-multiproduct.
www.pharmac.health.nz/assets/consultation-2014-08-07-multiproduct.pdf

About MSNZ:
For more information about MSNZ please email info@msnz.org.nz or call 0800 MS LINE (67 54 63).

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Review: Henry Rollins Burning Down The House

With his lantern jaw, close-cropped hair, and muscle-bound physique, Henry Rollins could not be further from the US Marine image his appearance might suggest. More>>

A Series Of Tubes: 150 Years Of The Cook Strait Cable

“It was a momentous achievement for its time. The successful connection came on the third attempt at laying the cable, and followed a near disaster when the first cable snapped - almost destroying the ship Weymouth in the process,” says Ms Adams. More>>

ALSO:

February 2017: Guns N' Roses - New Zealand Dates Announced

Founder Axl Rose and former members, Slash and Duff McKagan have regrouped for one of the century’s most anticipated tours... Rolling Stone said: "This was the real thing, the thing we'd all been waiting for: the triumphant return of one of the most important bands to cross rock music history. And it happened in our lifetime.” More>>

Werewolf: Brando, Peckinpah And Billy The Kid

Gordon Campbell: Initially, One-Eyed Jacks was supposed to have been directed by Stanley Kubrick from a script by Sam Peckinpah – yet it quickly became Brando’s baby... More>>

Book Awards: ANZAC Heroes Wins Margaret Mahy Book Of The Year

“Simply stunning, with gold-standard production values,” say the judges of the winner of this year’s Margaret Mahy Book of the Year Award in the prestigious New Zealand Book Awards for Children and Young Adults. ANZAC Heroes is also the winner of the Elsie Locke Award for the Best Book in the Non-Fiction category. More>>

Baby Animals: Hamilton Zoo Rhino Calf Named

Hamilton Zoo’s latest rhino calf has been named Samburu and he's being celebrated with a unique zoo experience... Samburu arrived after his mother Kito’s 16-month pregnancy and the calf brings the number of white rhinos at Hamilton Zoo to six. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news